We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
Impact Health is a mission-driven health policy and strategic consulting firm dedicated to improving health and well-being for all.
OUR SERVICES
Strategic Planning
Integrate mission-aligned policy expertise and political acumen into planning and executing your goals.
Government Contracting
Track record of success supporting states and municipalities in innovating or launching new programs.
Our proprietary method for tracking, aggregating, and analyzing state policy trends.
If you believe that every American deserves to be healthy and well, contact Impact Health Policy Partners to learn how our expertise can help you achieve your goals.
Policy Hub, managed by Impact Health Policy Partners, is the only comprehensive database of Federal health policy developments, cataloged by over 200 healthcare topics and programs. Regulations, reimbursement, grants, ACA implementation, hearing summaries, CRS Reports, pending legislation – you get it all here, with comprehensive, expert analysis.
Agency Finalizes Rule to Strengthen Oversight of Organ Procurement
The Centers for Medicare and Medicaid Services (CMS) released a final rule entitled “Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage (press release; fact sheet)” intended to clarify and strengthen federal oversight of organ procurement organizations (OPOs). What it is. CMS finalizes clarifications to outstanding procedural and technical questions on the implementation… (McClurg, October 30, 2026) #Public Health
Agency Approves Additional Labeling Changes for Menopausal Hormone Therapy Products
Today, the Food and Drug Administration (FDA) announced additional labeling changes for menopausal hormone therapy (MHT) products and outlined efforts to expand access to treatment. The announcement builds on the FDA’s February 2026 labeling actions and supports President Trump’s October 19 Executive Order, Advancing Women’s Health to Improve Outcomes in All Phases of Life. It also comes amid broader federal attention… (Eisen, October 30, 2026) #Food and Drug Administration, #Prescription Drugs, #Women’s Health